Abstract
This book testifies to the growing fund of knowledge, both at the basic scientific and at the clinical level, concerning the electrophysiological effects of antiarrhythmic drugs. A large number of antiarrhythmic agents are available for clinical use. All are of proven efficacy. Yet the question remains: is a particular agent going to benefit a particular patient?
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bastian BC, McFarlane PW, McLauchlan JH, Ballantyne D, Clark R, Hillis WS, Rae AP, Hutton I (1980) A prospective randomised trial of tocainide in patients following myocardial infarction. Am Heart J 100: 1017–1022
Beta-Blocker Heart Attack Trial Research Group (BHAT) (1982) A randomised trial of propranolol in patients with acute myocardial infarction. JAMA 247: 1707–1714
Bjerregaard P (1983) Premature beats in healthy subjects 40-79 years of age. Eur Heart J 3: 493–503
Bourke JP, Cowan JC, Tansuphaswadikul S, Campbell RWF (1987) Antiarrhythmic drug effects on left ventricular performance. Eur Heart J [Suppl A], 8: 105–111
Chamberlain DA, Jewitt DE, Julian DG, Campbell RWF, Boyle DMcC, Shanks RG (1980) Oral mexiletine in high-risk patients after myocardial infarction. Lancet 2: 1324–1327
Collaborative Group (1971) Phenytoin after recovery from myocardial infarction: controlled trial in 568 patients. Lancet 2: 1055–1057
Cowan JC, Bourke J, Campbell RWF (1987) Arrhythmogenic effects of antiarrhythmic drugs. Eur Heart J [Suppl A], 8: 133–136
Dewhurst NG, Hannan WJ, Muir AL (1984) Ventricular performance and prognosis after primary ventricular fibrillation complicating acute myocardial infarction. Eur Heart J 5: 275–281
Dubois C, Smeets JP, Demoulin C, Foidart G, Henrard L, Tulippe C, Preston L, earlier J, Kulbertus HE (1986) Incidence, clinical significance and prognosis of ventricular fibrillation in the early phase of myocardial infarction. Eur Heart J 7: 945–951
Friedman L, Yusuf S (1986) Does therapy directed by programmed electrical stimulation provide a satisfactory clinical response? Circulation [Suppl 2] 73: 59–66
Gallagher JJ, Sealy WC, Selle JG, Svenson RH, Zimmern SH (1986) Role of ablation techniques and surgery in the treatment of cardiac arrhythmias. In: Kulbertus HE (ed) Medical management of cardiac arrhythmias. Livingstone, Edinburgh, pp 253–283
Hinkle LE, Carver ST, Stevens M (1969) The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middle-aged men. Am J Cardiol 24: 629–650
Hugenholtz PG, Hagemeijer F, Lubsen J, Glaser B, van Durme JP, Bogaert MG (1978) One year follow-up in patients with persistent ventricular dysrhythmias after myo-cardial infarction treated with aprindine and placebo. In: Sandoe E, Julian DG, Bell J (eds) Management of ventricular tachycardia—role of mexiletine. Excerpta Medica, Amsterdam, pp 572–578
IMPACT Research Group (1984) International mexiletine and placebo antiarrhythmic coronary trial. I. Report on arrhythmia and other findings. J Am Coll Cardiol 4: 1148–1163
Kertes P, Hunt D (1984) Prophylaxis of primary ventricular fibrillation in acute myocardial infarction. The case against lignocaine. Br Heart J 52: 241–247
Koster RW, Dunning AJ (1985) Intramuscular lidocaine for the prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. N Engl J Med 313: 1105–1110
Lawrie DM, Higgins MR, Godman MJ, Oliver MF, Julian DG, Donald KW (1968) Ventricular fibrillation complicating acute myocardial infarction. Lancet 2: 523–528
Leinbach RC, Chamberlain DA, Kastor JA, Harthrone JW, Sanders CA (1969) A com-parison of the haemodynamic effects of ventricular and sequential A-V pacing in patients with heart block. Am Heart J 78: 502–508
May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL (1982) Secondary prevention after myocardial infarction: a review of long-term trials. Prog. Cardiovasc Dis 24: 331–352
Morganroth J, Horowitz LN (1984) Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53: 89B–94B
Moss AJ, Davis HT, DeCamilla J, Bawer LW (1979) Ventricular ectopic beats and their relation to sudden and non-sudden cardiac death after myocardial infarction. Circulation 60: 998–1003
Nademanee K, Hendrickson J, Hannan R, Singh BN (1982) Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneous ventricular tachyarrhythmias vs inconsistent abolition of induced VT. Am Heart J 103: 950–959
Nakano J, McCloy RB (1970) Effects of atrial and ventricular tachycardia on systemic and coronary circulations, and myocardial oxygen consumption in control dogs and in dogs with adrenergic blockade. Cardiovasc Res 4: 180–187
Norwegian Multicentre Research Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807
Peter T, Ross D, Duffield A, Luxton M, Harper R, Hunt D, Sloman G (1978) Effect on survival after myocardial infarction of long-term treatment with phenytoin. Br Heart J 40: 1356–1360
Rokseth R, Storstein O (1963) Quinidine therapy of chronic ventricular fibrillation. The occurrence and mechanisms of syncope. Arch Intern Med 111: 102–107
Ruskin JN, McGovern B, Garan H, DiMarco JP, Kelly E (1983) Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med 309: 1302–1306
Ryden L, Amman K, Conradson T-B, Hofvendsahl S, Mortensen O, Smedsard P (1980) Prophylaxis of ventricular tachyarrhythmias with intravenous and oral toc- ainide in patients with and recovering from acute myocardial infarction. Am Heart J 100: 1006–1012
Scheinman MM, Davis JC (1986) Catheter ablation for treatment of tachyarrhythmias: present role and potential promise. Circulation 73: 10–13
Schwartz PJ, Zara A, Grazi S, Lombardo M, Lotto A, Sbressa C, Zappa P (1985) Effect of ventricular fibrillation complicating acute myocardial infarction on long-term prognosis: importance of the site of infarction. Am J Cardiol 56: 384–389
Sheu SS, Lederer WJ (1985) Lidocaine’s negative inotropic and antiarrhythmic actions. Circ Res 57: 578–590
Soyeur D (1986) Haemodynamic consequences of cardiac arrhythmias. In: Kulbertus HE (ed) Medical management of cardiac arrhythmias. Livingstone, Edinburgh, pp 26–40
Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886–894
Winkle RA, Mason JW, Griffin JC, Ross D (1981) Malignant ventricular arrhythmias associated with the use of encainide. Am Heart J 102: 857–864
Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 27: 335–371
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Julian, D.G., Cowan, J.C. (1989). Successes and Limitations of Antiarrhythmic Drug Therapy. In: Vaughan Williams, E.M. (eds) Antiarrhythmic Drugs. Handbook of Experimental Pharmacology, vol 89. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73666-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-73666-7_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73668-1
Online ISBN: 978-3-642-73666-7
eBook Packages: Springer Book Archive